In the January 2016 edition of Financier Worldwide, Dr. Gregory K. Bell discusses how mergers and acquisitions can create shareholder value in the life sciences sector. The roundtable discussion is moderated by James C. Greenwood, President and CEO of the Biotechnology Innovation Organization (BIO). To read the article, click the link below.
Response to the European Commission’s targeted consultation on revising its merger guidelines
Their recommendations include: Using simultaneous vGUPPIs to account for feedback effects between raising rivals’ costs (RRC) incentives and elimination of...